Dissemin is shutting down on January 1st, 2025

Published in

American Society of Hematology, Blood Advances, 2023

DOI: 10.1182/bloodadvances.2023010303

Links

Tools

Export citation

Search in Google Scholar

Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia

Journal article published in 2023 by Shai Shimony ORCID, Daniel J. DeAngelo ORCID, Marlise R. Luskin ORCID
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Red circle
Postprint: archiving forbidden
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma (T-ALL/LBL) is a rare hematologic malignancy most commonly affecting adolescent and young adult (AYA) males. Outcomes are dismal for patients who relapse so improvement in treatment is needed. Nelarabine, a pro-drug of the deoxyguanosine analogue ara-G, is uniquely toxic to T-lymphoblasts, compared to B-lymphoblasts and normal lymphocytes, and has been developed for the treatment of T-ALL/LBL. Based on phase I and II trials in children and adults, single-agent nelarabine is approved for treatment of patients with R/R T-ALL/LBL, with the major adverse effect being central and peripheral neurotoxicity. Since its approval in 2005, nelarabine has been studied in combination with other chemotherapy agents for relapsed disease and is also being studied as a component of initial treatment in pediatric and adult patients. Here, we review current data with nelarabine and present our approach to the use of nelarabine in the treatment of patients with T-ALL/LBL.